Kellie Bishop, MD
Psychiatry · Hilton Head Island, SCNPI 1245413723
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,500 of the $13,150 with a category attached, or 72.2%. AbbVie accounts for 78.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $5,719 and has fallen 88.7% since, to $646 in 2025. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $72.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Teva Pharmaceuticals USA, Inc.$606
- Otsuka America Pharmaceutical, Inc.$458
- Vanda Pharmaceuticals Inc.$368
- Johnson & Johnson$332
- Alkermes, Inc.$205
- plus $835 from 9 others
What the payments were for
- Speaking & faculty fees$9,50072%
- Food & beverage$3,50727%
- Education$1431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $10,346 |
| Teva Pharmaceuticals USA, Inc. | 29 | $606 |
| Otsuka America Pharmaceutical, Inc. | 19 | $458 |
| Vanda Pharmaceuticals Inc. | 12 | $368 |
| Johnson & Johnson | 18 | $332 |
| Alkermes, Inc. | 9 | $205 |
| Axsome Therapeutics, Inc. | 5 | $201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $189 |
| Lundbeck LLC | 5 | $108 |
| Neurocrine Biosciences, Inc. | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $43 |
| Bausch Health US, LLC | 2 | $39 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,150 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 54 | $84,116 |
| Abilify MaintenaAripiprazole | 25 | $65,930 |
| VraylarCariprazine Hcl | 28 | $40,783 |
| Risperdal ConstaRisperidone Microspheres | 13 | $32,541 |
| RexultiBrexpiprazole | 20 | $28,492 |
| CaplytaLumateperone Tosylate | 11 | $17,597 |
| Aripiprazole | 74 | $8,444 |
| Haloperidol Decanoate | 101 | $5,199 |
| Quetiapine Fumarate | 157 | $2,474 |
| Divalproex Sodium | 81 | $2,436 |
| Clozapine | 20 | $1,939 |
| Fluphenazine Decanoate | 18 | $1,939 |
| Olanzapine | 148 | $1,883 |
| Haloperidol | 69 | $1,522 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $1,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $332 | $116,65867 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $458 | $94,42245 claims |
| AbbVieVraylar | $10,346 | $40,78328 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $189 | $17,59711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Hilton Head Island
- Ravindra SrivastavaHilton Head Island$7K
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Nikunjkumar ModiFlorence$133K
- Jacobo MintzerCharleston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.